Clinical Trials Logo

Clinical Trial Summary

Ronacaleret is an orally administered CaSR antagonist which has previously been demonstrated to transiently increase PTH in both animals and humans. Additional studies in post-menopausal women and patients with distal radial fractures have demonstrated both anabolic and catabolic effects on bone biomarkers and scans of bone density. Based on ronacalerets ability to interact with the CaSR inducing PTH release and activating endogenous bone metabolism of both osteoblasts and osteoclasts, it is our intention to evaluate the impact activation of this pathway has on mobilization of Hematopoietic stem cell (HSCs) into the periphery.

This is an adaptive, phase I, randomized, single centre, double-blind dose finding, parallel-group, multi-cohort placebo controlled study of the efficacy and safety of ronacaleret in up to 45 healthy human volunteers. Cohorts of eligible subjects will be studied for periods up to 28 days. Total daily doses of ronacaleret will range from 100mg, up to 400mg and be administered for a maximum of 28days. The first part of this study will evaluate several doses and schedules of ronacaleret, run in parallel, with respect to their ability to affect mobilization of CD34+ cells into the peripheral circulation. In subsequent cohorts of the study we will utilize information obtained from previous cohorts to further refine and optimise those dosing paradigms which show efficacy. For the first cohort of study participants; the study will commence with 6 days of dosing in an inpatient setting followed by 21 days of continued dosing and evaluation as an outpatient, with a series of regularly scheduled visits, with the final visit on day 28. The study period will include evaluations of pharmacokinetic and pharmacodynamic parameters along with standard laboratory and safety evaluations. The second cohort may be treated with ronacaleret for periods ranging from 14 to 28 days in order to optimise the treatment paradigm with respect to pharmacodynamic efficacy. The PK/PD of each group in cohort one will be utilized to make adjustments in the total daily dose, dose frequency and or duration of dosing investigated in cohort 2. Decisions will be made as to dropping doses based on the PK/PD results and any safety considerations. An initial equal randomization amongst groups within the first cohort may be adjusted to allow for other randomization strategies as various doses and schedules are assessed.

The objective of this study is to characterise the dose-response curve for ronacaleret with respect to safety and efficacy based on changes in peripheral CD34+ cell counts. Results obtained from this study will inform us: of optimized doses, schedules, and durations of treatment for future studies. Additional cohorts may be added to further explore the dose schedule and duration if required. The exact number of cohorts studied will depend on the results obtain from the prior groups and the desire to explore a variety of doses and schedules. The aims of the present study (CR9115166) include an assessment of the pharmacodynamic effects (mobilization of CD34+ cells), safety, tolerability, and pharmacokinetics of ronacaleret in healthy human volunteers.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01466335
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 1
Start date October 27, 2011
Completion date March 5, 2012

See also
  Status Clinical Trial Phase
Recruiting NCT06148610 - Evaluation of the Impact of the Use of NewSpringForMe on Transplanted Patients' Quality of Life and Support
Completed NCT02212236 - Psychological Intervention for Distress During HSCT Phase 2
Completed NCT00023530 - Blood and Marrow Transplant Clinical Research Network N/A
Withdrawn NCT02682953 - Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers Phase 2
Completed NCT00775632 - Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants Phase 2
Completed NCT00048256 - Relationship Between Personality and Coping Styles in Bone Marrow Transplant Candidates N/A
Completed NCT00004994 - Comparison of Quality of Life in Patients Undergoing More Intensive Versus Less Intensive Chemotherapy and Radiation Preceding a Bone Marrow Transplant N/A
Completed NCT04039100 - Family Caregiver Ambassador Support for Family Caregivers of Patients With Hematological Disease N/A
Completed NCT04535570 - Evolution of the Energy Expenditure During Hematopoietic Stem Cell Transplantation
Recruiting NCT06118853 - Impact of Yoga and Gentle Massage Practices on Symptom Management in Patients Undergoing HSCT N/A
Active, not recruiting NCT01016093 - Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major Patients Phase 2/Phase 3
Completed NCT01015183 - Prevention Chemotherapy Induced Mucositis by Zinc Sulfate Phase 2/Phase 3
Completed NCT00843180 - Massage for Pediatric Oncology N/A
Completed NCT00000591 - T-Cell Depletion in Unrelated Donor Marrow Transplantation Phase 3
Completed NCT04474730 - Physical Activity Monitoring Among BMT Patients N/A
Completed NCT02733744 - Fecal Microbiota Transplantation After HSCT Early Phase 1
Active, not recruiting NCT02319226 - Toward Immune Biomarkers for Tolerance and GvHD in Humans
Recruiting NCT00673348 - Therapeutic Drug Monitoring (TDM) of Voriconazole and Correlation With CYP2C19 Genotype in Korean Populations N/A
Completed NCT00005556 - Retention of Bone Marrow Donors in a National Registry N/A
Completed NCT05391347 - Effects of Orange Oil Aromatherapy on the Pain and Anxiety N/A